Show simple item record

The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers

dc.contributor.authorKennedy, Jeffrey S.
dc.contributor.authorCo, Mary Dawn T.
dc.contributor.authorGreen, Sharone
dc.contributor.authorLongtine, Karen J.
dc.contributor.authorLongtine, Jaclyn K.
dc.contributor.authorO'Neill, Melissa A.
dc.contributor.authorAdams, Janice P.
dc.contributor.authorRothman, Alan L.
dc.contributor.authorYu, Qiao
dc.contributor.authorJohnson-Leva, Renita
dc.contributor.authorPal, Ranajit
dc.contributor.authorWang, Shixia
dc.contributor.authorLu, Shan
dc.contributor.authorMarkham, Phillip
dc.date2022-08-11T08:09:37.000
dc.date.accessioned2022-08-23T16:37:59Z
dc.date.available2022-08-23T16:37:59Z
dc.date.issued2008-07-01
dc.date.submitted2009-10-29
dc.identifier.citation<p>Vaccine. 2008 Aug 18;26(35):4420-4. Epub 2008 Jun 25. <a href="http://dx.doi.org/10.1016/j.vaccine.2008.05.090">Link to article on publisher's site</a></p>
dc.identifier.issn0264-410X (Print)
dc.identifier.doi10.1016/j.vaccine.2008.05.090
dc.identifier.pmid18588934
dc.identifier.urihttp://hdl.handle.net/20.500.14038/39145
dc.description.abstractThis report describes the safety observations following administration of a polyvalent DNA prime-protein boost HIV-1 vaccine formulated with adjuvant QS21. Local injection site reactions were the most common (65% of subjects), and included type IV delayed-type hypersensitivity (DTH) reactions at prior DNA inoculation sites in 12 of 28 (43%) subjects following protein vaccination. Systemic reactions revealed two cases of vasculitis temporally related to inoculation with recombinant Env protein+QS21 adjuvant. Questions remain regarding the cause of the vasculitis, but the unique DTH observation may have contributed to the high level of immune responses previously reported for this vaccine.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=18588934&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2571083/
dc.subjectAIDS Vaccines
dc.subjectAdjuvants, Immunologic
dc.subjectAdult
dc.subjectFemale
dc.subjectHuman Experimentation
dc.subjectHumans
dc.subjectHypersensitivity, Delayed
dc.subjectImmunization, Secondary
dc.subjectMale
dc.subjectSaponins
dc.subjectSkin
dc.subjectVaccines, DNA
dc.subjectVaccines, Subunit
dc.subjectVasculitis
dc.subjectLife Sciences
dc.subjectMedicine and Health Sciences
dc.titleThe safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers
dc.typeJournal Article
dc.source.journaltitleVaccine
dc.source.volume26
dc.source.issue35
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/1959
dc.identifier.contextkey1050695
html.description.abstract<p>This report describes the safety observations following administration of a polyvalent DNA prime-protein boost HIV-1 vaccine formulated with adjuvant QS21. Local injection site reactions were the most common (65% of subjects), and included type IV delayed-type hypersensitivity (DTH) reactions at prior DNA inoculation sites in 12 of 28 (43%) subjects following protein vaccination. Systemic reactions revealed two cases of vasculitis temporally related to inoculation with recombinant Env protein+QS21 adjuvant. Questions remain regarding the cause of the vasculitis, but the unique DTH observation may have contributed to the high level of immune responses previously reported for this vaccine.</p>
dc.identifier.submissionpathoapubs/1959
dc.contributor.departmentDepartment of Anesthesiology
dc.contributor.departmentCenter for Infectious Disease and Vaccine Research
dc.source.pages4420-4


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record